Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29845505 | 1.00 | LMNA (0.56) | LMNACHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL14489601 | 0.98 | LMNA (0.55) | LMNACHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL13628924 | 0.98 | LMNA (0.55) | LMNACHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL13842135 | 0.96 | LMNA (0.52) | LMNACHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL3956434 | 0.88 | CHRM2 (0.47) | LMNACHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1999106 | 0.87 | LMNA (0.55) | LMNACHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL10808122 | 0.85 | LMNA (0.54) | LMNACHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL10299132 | 0.85 | LMNA (0.57) | LMNACHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL3961366 | 0.84 | CHRM2 (0.47) | LMNACHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL3992289 | 0.84 | CHRM2 (0.47) | LMNACHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112129849-B | Method for detecting phenylacetic acid and 2-cyclopentylidene-2-phenylacetic acid in (1-hydroxycyclopentyl) phenylacetic acid | 山东绅联生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-112129849-A | Method for detecting phenylacetic acid and 2-cyclopentylidene-2-phenylacetic acid in (1-hydroxycyclopentyl) phenylacetic acid | 山东绅联生物科技有限公司 | 2020-12-25 | — | — | CN | claimed |
| EP-2822653-A2 | NEW C-GLYCOSYLPOLYPHENOL ANTIDIABETIC AGENTS, EFFECT ON GLUCOSE TOLERANCE AND INTERACTION WITH BETA-AMYLOID. THERAPEUTIC APPLICATIONS OF THE SYNTHESIZED AGENT(S) AND OF GENISTA TENERA ETHYL ACETATE EXTRACTS CONTAINING SOME OF THOSE AGENTS | Universidade de Lisboa (PT) | 2015-01-14 | — | — | EP | claimed |
| WO-2013132470-A2 | NEW C-GLYCOSYLPOLYPHENOL ANTIDIABETIC AGENTS, EFFECT ON GLUCOSE TOLERANCE AND INTERACTION WITH BETA-AMYLOID. THERAPEUTIC APPLICATIONS OF THE SYNTHESIZED AGENT(S) AND OF GENISTA TENERA ETHYL ACETATE EXTRACTS CONTAINING SOME OF THOSE AGENTS | UNIVERSIDADE DE LISBOA (PT) | 2013-09-12 | — | — | WO | claimed |
| US-20240094559-A1 | CONTACT LENS AND PRODUCT THEREOF | LARGAN MEDICAL CO., LTD. (TW) | 2024-03-21 | — | — | US | disclosed |
| US-11867985-B2 | Contact lens and product thereof | LARGAN MEDICAL CO., LTD. (TW) | 2024-01-09 | — | — | US | disclosed |
| US-20230393417-A1 | MULTIFOCAL CONTACT LENS AND CONTACT LENS PRODUCT | LARGAN MEDICAL CO., LTD. (TW) | 2023-12-07 | — | — | US | disclosed |
| US-11782294-B2 | Multifocal contact lens and contact lens product | LARGAN MEDICAL CO., LTD. (TW) | 2023-10-10 | — | — | US | disclosed |
| US-20230004022-A1 | CONTACT LENS PRODUCT | LARGAN MEDICAL CO., LTD. (TW) | 2023-01-05 | — | — | US | disclosed |
| CN-112129849-B | Method for detecting phenylacetic acid and 2-cyclopentylidene-2-phenylacetic acid in (1-hydroxycyclopentyl) phenylacetic acid | 山东绅联生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-112129849-B | Method for detecting phenylacetic acid and 2-cyclopentylidene-2-phenylacetic acid in (1-hydroxycyclopentyl) phenylacetic acid | 山东绅联生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-112129849-B | Method for detecting phenylacetic acid and 2-cyclopentylidene-2-phenylacetic acid in (1-hydroxycyclopentyl) phenylacetic acid | 山东绅联生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| EP-1546099-B1 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-12-31 | — | — | EP | disclosed |
| US-7399779-B2 | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-07-15 | — | — | US | disclosed |
| US-20070004791-A1 | 3,6-disubstituted azabicyclo {3.1.0} hexane derivatives useful as muscarnic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-04 | — | — | US | disclosed |
| EP-1546099-A4 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-08-02 | — | — | EP | disclosed |
| EP-1546099-A2 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004004629-A2 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | LMNA 3118/4885CHRM2 4875/4885CHRM1 4854/4885 |
| US-20070004791-A1 | 3,6-disubstituted azabicyclo {3.1.0} hexane derivatives useful as muscarnic receptor antagonists | CHRM3, CHRM5, CHRM2 | LMNA 3111/4885CHRM2 3/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.